HSP90 inhibitors selectively kill cancer cells compared to normal cells, and have also demonstrated antitumor effects towards lymphomas, melanomas, as well as some solid tumors (e.g., breast cancer, non-small-cell lung cancer) (16, 17). This evidence concerns the gene HSP90AA1 and non-small cell lung carcinoma.